Results of the open-label phase II trial, SGNTUC-019, "evaluating tucatinib in combination with trastuzumab" in patients with HER2-mutated metastatic breast cancer, showed that this form of treatment was well tolerated with diarrhea noted as the most common adverse event. In addition, study authors noted that most events had a grade 1 severity, which were managed with standard clinical care; grade 3 occurrence was noted in 13% of cases.
To learn more about this study, click here.
Source mentioned:
Okines AFC, Curigliano G, Mizuno N, et al. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nature Medicine; Published online 17 January 2025. DOI: https://doi.org/10.1038/s41591-024-03462-0
A chemotherapy-free combination showing durable responses in HER2-mutated metastatic breast cancer is encouraging, especially with most adverse events at grade 1 and manageable with standard care. Diarrhea as the most common event is a trade-off many patients would accept against cytotoxic chemotherapy. Following how oncbrothers track these targeted combinations is useful, because HER2-mutated disease outside the classic HER2-positive definition is still an evolving treatment space.
ReplyDelete